Tilsotolimod

DRUG4 trials

Sponsors

Idera Pharmaceuticals, Inc., A.J.M. van den Eertwegh, AbbVie, Gustave Roussy, Cancer Campus, Grand Paris

Conditions

Advanced CancerAdvanced Solid Tumors CancerMalignant MelanomaSolid Tumor

Phase 1

A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

CompletedNCT04196283

AbbVieAdvanced Solid Tumors Cancer

Start: 2020-01-22End: 2022-10-27Updated: 2023-02-27

Intratumoral Tilsotolimod, a TLR-9 Agonist, Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced Cancers

TerminatedNCT04270864

Gustave Roussy, Cancer Campus, Grand ParisAdvanced Cancer

Start: 2020-04-10End: 2023-09-25Updated: 2024-10-18

Phase 2

Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)

Active, not recruitingNCT03865082

Idera Pharmaceuticals, Inc.Solid Tumor

Start: 2019-10-29End: 2022-04-30Target: 30Updated: 2022-02-17

A Randomized Controlled Phase II Trial With Intradermal IMO-2125 in Pathological Tumor Stage (p) T3-4 cN0M0 Melanoma

RecruitingNCT04126876

A.J.M. van den EertweghMalignant Melanoma

Start: 2020-01-22End: 2031-11-01Target: 214Updated: 2021-04-15

Related Papers

Abstract CT134: Tilsotolimod engages the TLR9 pathway to promote antigen presentation and Type-I IFN signaling in solid tumors

Cancer Research2020-08-159 citations

Abstract CT265: A phase 2 multicenter study to evaluate the efficacy of tilsotolimod in combination with nivolumab and ipilimumab for treatment of microsatellite-stable colorectal cancer (ILLUMINATE-206)

Cancer Research2020-08-153 citations